Portfolio of Technologies
Please use the below filters to navigate a sampling of BU’s companies and available technologies by Sector, Type (license/start-up) and Status (commercialized/seeking partnership).
Ranging from clinical process improvement to cutting edge patient interaction technologies, Engineered Care improves patient care by bridging communications between the inpatient and outpatient care team, optimizing clinical workflows, and empowering patients in self-care management through its Virtual Health Educator tool.
Acpharis, Inc. provides both routine and innovative applications of computational methods to the biomedical problems investigated by its partners. Using proprietary tools the company: explores the druggability of target proteins selected by its partners, identifies and characterizes druggable binding sites, and selects functional groups to be used for the design of targeted compound libraries.
Founded in 2007 in Cambridge, MA, Sand 9 is the technology leader in precision MEMS timing. Targeting a $4+B market opportunity with its piezoelectric MEMS products—which clock wireless and wired systems in mobile, low power wireless, communications infrastructure, industrial and military markets—Sand 9 outperforms both legacy quartz timing devices and other MEMS-based solutions. Sand 9’s MEMS timing products enhance quality and performance, simplify system design, and promote space and power savings in integrated electronic systems.
Providing dynamic solutions for data-rich businesses, so you can gain a competitive advantage in creating more meaningful customer experiences. Through a new class of business analytic applications embedded with powerful data science, you have the power to immediately distill data into actionable insight
Symphogen is leading the development of antibody mixture therapeutics to improve the treatment of serious human diseases. Symphogen’s growing pipeline of cancer programs reflect a new approach to fighting cancer with unique mechanisms based on multiple simultaneous attacks on tumors.
HemaQuest is a San Diego and Seattle-based biopharmaceutical company developing proprietary small molecules targeting specific genes that enable the treatment of serious and life threatening hematologic disorders. Currently, the Company has one therapeutic in Phase 2 clinical development – HQK-1001 for sickle cell disease and beta thalassemia.
Allegro Diagnostics Corp. is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests to support the diagnosis and management of lung cancer
Planarization technique for III-nitride materials that produces fewer scratches compared to a chemo mechanical process and can achieve a 99% roughness reduction of up to 1nm without subsurface damage.